This Cathie Wood Stock Is Down 36% Over the Past 2 Years. She Still Can’t Get Enough.
Since the beginning of 2026, shares of CRISPR Therapeutics (CRSP) are down by about 11%. While that’s not a great start to the year, there are plenty of reasons to be bullish. For one, Cathie Wood can’t get enough of CRSP stock, recently picking up another 438,000 shares across the ARK Innovation ETF (ARKK) and ARK Genomic Revolution ETF (ARKG).